BDX vs KNSA: fair value comparison
Becton, Dickinson and Company and Kiniksa Pharmaceuticals International, plc · Updated 2026-09-07
BDX currently screens as undervalued while KNSA screens as fairly valued. Within Healthcare, BDX currently sits closer to the top of our discount ranking. BDX carries the stronger quality grade.
| BDX | KNSA | |
|---|---|---|
| Verdict | Undervalued | Fairly valued |
| Last price | $184.74 | $73.41 |
| 12-month range | $145.33–$201.91 | $37.47–$73.41 |
| Sector rank | #53 of 113 Healthcare | #58 of 113 Healthcare |
| Quality grade | B | D |
| Leverage | Moderate | Low |
| Margin trend | Expanding | — |
| Revenue growth | Modest | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Undervalued | — |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: BDX fair value analysis · KNSA fair value analysis